HK1085658A1 - Pharmaceutical compositions comprising 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors - Google Patents
Pharmaceutical compositions comprising 1-aminocyclohexane derivatives and acetylcholinesterase inhibitorsInfo
- Publication number
- HK1085658A1 HK1085658A1 HK06105633A HK06105633A HK1085658A1 HK 1085658 A1 HK1085658 A1 HK 1085658A1 HK 06105633 A HK06105633 A HK 06105633A HK 06105633 A HK06105633 A HK 06105633A HK 1085658 A1 HK1085658 A1 HK 1085658A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical compositions
- acetylcholinesterase inhibitors
- aminocyclohexane derivatives
- aminocyclohexane
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42091802P | 2002-10-24 | 2002-10-24 | |
| PCT/GB2003/004549 WO2004037234A2 (en) | 2002-10-24 | 2003-10-23 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1085658A1 true HK1085658A1 (en) | 2006-09-01 |
Family
ID=32176649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK06105633A HK1085658A1 (en) | 2002-10-24 | 2006-05-16 | Pharmaceutical compositions comprising 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20040087658A1 (ko) |
| EP (2) | EP1556019A2 (ko) |
| JP (2) | JP2006506378A (ko) |
| KR (2) | KR100777904B1 (ko) |
| CN (1) | CN100339070C (ko) |
| AU (1) | AU2003274353B2 (ko) |
| CA (1) | CA2502432A1 (ko) |
| EA (1) | EA008863B1 (ko) |
| GE (1) | GEP20094759B (ko) |
| HK (1) | HK1085658A1 (ko) |
| MX (1) | MXPA04006900A (ko) |
| NO (1) | NO20052462L (ko) |
| PL (1) | PL376476A1 (ko) |
| TW (1) | TW200418446A (ko) |
| UA (1) | UA83645C2 (ko) |
| WO (1) | WO2004037234A2 (ko) |
| ZA (1) | ZA200503204B (ko) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| AU2003274353B2 (en) * | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| WO2005079779A1 (en) * | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
| DK1703902T3 (da) * | 2004-01-05 | 2011-02-14 | Merz Pharma Gmbh & Co Kgaa | Memantin til behandling af mild til moderat Alzheimer's sygdom |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| EP1827385B1 (en) * | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| US20060211650A1 (en) * | 2004-12-16 | 2006-09-21 | Forest Laboratories, Inc. | Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof |
| CN101087618A (zh) * | 2004-12-23 | 2007-12-12 | 航行药物公司 | 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用 |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| WO2006121560A2 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| NZ562120A (en) * | 2005-04-28 | 2010-07-30 | Eisai R&D Man Co Ltd | Composition comprising donepezil and memantine as antidementia agents |
| US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| ATE481094T1 (de) | 2005-12-22 | 2010-10-15 | Kiacta Sarl | Behandlung von diabetischer nephropathie |
| MX2009004516A (es) * | 2006-10-27 | 2009-08-12 | Medivation Neurology Inc | Metodos y terapias de combinacion para tratar enfermedad de alzheimer. |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CA2690110A1 (en) * | 2007-07-13 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists for neuropathic pain |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| TW201010691A (en) * | 2008-06-12 | 2010-03-16 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders |
| US20110178179A1 (en) * | 2008-09-10 | 2011-07-21 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| EP3006023B1 (en) * | 2009-01-20 | 2019-06-26 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Sorbic acid and derivatives thereof to enhance the activity of a neuropharmaceutical |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| TWI491395B (zh) | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
| BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
| WO2011100373A1 (en) * | 2010-02-09 | 2011-08-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| TR201001117A1 (tr) | 2010-02-15 | 2011-09-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Dimebolin ve memantin kombinasyonları |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| WO2011147999A1 (es) * | 2010-05-24 | 2011-12-01 | Farmalider, S.A. | Compuesto inhibidor de la activación de la enzima erk1/2 para su uso en el tratamiento de enfermedades neurodegenerativas |
| WO2012068161A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| JP6604957B2 (ja) | 2014-02-04 | 2019-11-13 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | ドネペジル組成物及びアルツハイマー病を治療する方法 |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CA2990004C (en) | 2015-06-19 | 2024-04-23 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| KR101882224B1 (ko) | 2015-09-02 | 2018-07-26 | 한국프라임제약주식회사 | 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물 |
| KR102338171B1 (ko) | 2016-06-13 | 2021-12-09 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | 벤조산리튬의 공-결정 및 그의 용도 |
| ES2936094T3 (es) | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
| WO2017223402A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| AU2017302305A1 (en) | 2016-07-27 | 2019-02-14 | Corium, LLC. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| RU2764764C2 (ru) | 2016-07-27 | 2022-01-21 | Кориум Интернэшнл, Инк. | Трансдермальные системы доставки мемантина |
| WO2018022817A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Donepezil transdermal delivery system |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| US20200166526A1 (en) * | 2017-07-25 | 2020-05-28 | William Beaumont Hospital | Methods for diagnosing and treating alzheimer's disease |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| CA3086163A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
| WO2020240505A1 (en) | 2019-05-31 | 2020-12-03 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Immediate release fixed-dose combination of memantine and donepezil |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH603545A5 (ko) | 1972-04-20 | 1978-08-31 | Merz & Co | |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| NL195004C (nl) * | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| US4849222A (en) | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
| US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| DK0724432T3 (da) | 1993-10-22 | 2003-01-27 | Genentech Inc | Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner |
| US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| CZ293248B6 (cs) | 1997-06-30 | 2004-03-17 | Merz Pharma Gmbh & Co. Kgaa | 1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi |
| EA005291B1 (ru) * | 1999-03-31 | 2004-12-30 | Янссен Фармацевтика Н.В. | Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением |
| TW593223B (en) * | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| AU2003227516B2 (en) * | 2002-05-31 | 2008-03-20 | H. Lundbeck A/S | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| AU2003274353B2 (en) * | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| JP2010524844A (ja) * | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 認知症のためのシンナミド化合物 |
-
2003
- 2003-10-23 AU AU2003274353A patent/AU2003274353B2/en not_active Ceased
- 2003-10-23 CN CNB200380104613XA patent/CN100339070C/zh not_active Expired - Fee Related
- 2003-10-23 CA CA002502432A patent/CA2502432A1/en not_active Abandoned
- 2003-10-23 EP EP03758338A patent/EP1556019A2/en not_active Withdrawn
- 2003-10-23 EP EP10181505A patent/EP2260839A3/en not_active Withdrawn
- 2003-10-23 TW TW092129457A patent/TW200418446A/zh unknown
- 2003-10-23 WO PCT/GB2003/004549 patent/WO2004037234A2/en active IP Right Grant
- 2003-10-23 US US10/691,895 patent/US20040087658A1/en not_active Abandoned
- 2003-10-23 EA EA200500699A patent/EA008863B1/ru unknown
- 2003-10-23 MX MXPA04006900A patent/MXPA04006900A/es active IP Right Grant
- 2003-10-23 GE GEAP20038812A patent/GEP20094759B/en unknown
- 2003-10-23 UA UAA200504854A patent/UA83645C2/ru unknown
- 2003-10-23 PL PL03376476A patent/PL376476A1/xx not_active Application Discontinuation
- 2003-10-23 KR KR1020057007052A patent/KR100777904B1/ko not_active IP Right Cessation
- 2003-10-23 KR KR1020077016542A patent/KR100852834B1/ko not_active IP Right Cessation
- 2003-10-23 JP JP2004546158A patent/JP2006506378A/ja active Pending
-
2005
- 2005-04-20 ZA ZA200503204A patent/ZA200503204B/en unknown
- 2005-05-23 NO NO20052462A patent/NO20052462L/no not_active Application Discontinuation
-
2006
- 2006-05-16 HK HK06105633A patent/HK1085658A1/xx not_active IP Right Cessation
-
2008
- 2008-02-27 US US12/072,539 patent/US20090124659A1/en not_active Abandoned
-
2010
- 2010-03-22 US US12/661,639 patent/US20100227852A1/en not_active Abandoned
-
2011
- 2011-09-07 JP JP2011195242A patent/JP2011246491A/ja active Pending
-
2014
- 2014-05-16 US US14/280,405 patent/US20140371260A1/en not_active Abandoned
-
2016
- 2016-01-28 US US15/008,646 patent/US20160136144A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/178,606 patent/US20210169864A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200418446A (en) | 2004-10-01 |
| EA200500699A1 (ru) | 2005-10-27 |
| US20140371260A1 (en) | 2014-12-18 |
| EP1556019A2 (en) | 2005-07-27 |
| US20100227852A1 (en) | 2010-09-09 |
| US20160136144A1 (en) | 2016-05-19 |
| EP2260839A2 (en) | 2010-12-15 |
| WO2004037234A3 (en) | 2004-08-05 |
| GEP20094759B (en) | 2009-08-25 |
| CA2502432A1 (en) | 2004-05-06 |
| EP2260839A3 (en) | 2012-05-02 |
| ZA200503204B (en) | 2006-07-26 |
| JP2011246491A (ja) | 2011-12-08 |
| AU2003274353A1 (en) | 2004-05-13 |
| US20210169864A1 (en) | 2021-06-10 |
| CN1720035A (zh) | 2006-01-11 |
| KR100777904B1 (ko) | 2007-11-28 |
| WO2004037234A2 (en) | 2004-05-06 |
| AU2003274353B2 (en) | 2007-04-05 |
| EA008863B1 (ru) | 2007-08-31 |
| NO20052462D0 (no) | 2005-05-23 |
| CN100339070C (zh) | 2007-09-26 |
| JP2006506378A (ja) | 2006-02-23 |
| US20090124659A1 (en) | 2009-05-14 |
| US20040087658A1 (en) | 2004-05-06 |
| MXPA04006900A (es) | 2004-10-15 |
| KR100852834B1 (ko) | 2008-08-18 |
| PL376476A1 (en) | 2005-12-27 |
| KR20070087161A (ko) | 2007-08-27 |
| NO20052462L (no) | 2005-07-20 |
| KR20050072770A (ko) | 2005-07-12 |
| UA83645C2 (ru) | 2008-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1085658A1 (en) | Pharmaceutical compositions comprising 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | |
| IL168477A (en) | Isoindoline derivatives and pharmaceutical compositions comprising them | |
| HUP0400384A3 (en) | Benzamidine derivative and pharmaceutical compositions containing them and their use | |
| IL162548A0 (en) | 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same | |
| IL166482A0 (en) | Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same | |
| IL164987A0 (en) | Proline derivatives and pharmaceutical compositions containing | |
| GB2389530B (en) | Pharmaceutical compositions | |
| HUP0500173A3 (en) | Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them | |
| IL164185A0 (en) | Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives | |
| IL163117A (en) | Indazole derivatives and pharmaceutical compositions containing the same | |
| HK1089394A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| IL170313A (en) | Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them | |
| PL375860A1 (en) | Benzodiazepine derivatives and pharmaceutical compositions containing them | |
| IL173602A0 (en) | Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same | |
| IL173627A0 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same | |
| IL173051A0 (en) | N-glucoside derivatives and pharmaceutical compositions containing the same | |
| IL171997A0 (en) | Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same | |
| IL174445A0 (en) | Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same | |
| IL175214A0 (en) | 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same | |
| IL172159A0 (en) | 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same | |
| IL166512A0 (en) | Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same | |
| IL165986A0 (en) | Isoquinoline and quinazoline derivatives and pharmaceutical compositions containing the same | |
| IL197889A (en) | Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same | |
| GB2391473B (en) | Pharmaceutical compositions | |
| EP1496913A4 (en) | NEUROPROTECTIVE PHARMACEUTICAL SPIROSTENOL COMPOSITIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20111023 |